Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)

Launched by LANCASTER GENERAL HOSPITAL · May 28, 2024

Keywords

ClinConnect Summary

This study aims to determine if platelet function has improved following platelet transfusion by prospectively performing repeat thromboelastographic with platelet mapping (TEG-PM) assays on all patients consented and enrolled in the study. This study will also examine the rate of progression or stability of ICH on repeat head CT following platelet administration and will aid in the determination of a potential association between repeat CT head findings and the repeat TEG-PM results.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for Interventional Portion of Study:
• • Patients ≥ 18 years of age who present with TICH meeting Brain Injury Guidelines (BIG) 2 or 3 head bleed criteria
• • Currently on antiplatelet medication on admission
• • Must have taken this antiplatelet medication within the past 48 hours prior to presentation
• • Patients who have AA and/or ADP inhibition of 70% or greater and Maximum Amplitude (MA) \<50 will then receive a platelet transfusion and a repeat TEG-PM 1hr after transfusion
• Exclusion Criteria for Interventional Portion of Study:
• • Under 18 years of age
• • Have a known bleeding diatheses
• • Current therapeutic anticoagulation use
• • Do not know the time of their last antiplatelet medication dose
• • Patients or their proxy who are unable to provide consent
• • Patients with concomitant long bone fractures or solid organ injuries
• Inclusion Criteria for Retrospective Portion of Study:
• • • Patients with a TICH who are 18 years of age or older
• Exclusion Criteria for Retrospective Portion of Study:
• • Abbreviated Injury Scale (AIS) \>1 in body regions other than head because of concomitant long bone fracture or solid organ injury
• • Under 18 years of age